Acid-generating fluid loss control additives and associated methods

Information

  • Patent Grant
  • 7686080
  • Patent Number
    7,686,080
  • Date Filed
    Thursday, November 9, 2006
    18 years ago
  • Date Issued
    Tuesday, March 30, 2010
    14 years ago
Abstract
Many methods are provided herein including a method of providing fluid loss control comprising: providing a treatment fluid; adding to the treatment fluid an acid-generating fluid loss control additive comprising an acid-generating component wherein the acid-generating fluid loss control additive forms droplets in the treatment fluid; and placing the treatment fluid into a subterranean formation. Other methods are provided as well.
Description
BACKGROUND OF THE INVENTION

The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.


Providing effective fluid-loss control for well treatment fluids is highly desirable. A “treatment fluid” is a fluid used in a subterranean application for any purpose. The term “treatment” as used herein does not imply any particular action by the fluid or any component thereof. Fluid-loss control materials are often added to treatment fluids to aid in fluid loss control. These are additives that are generally designed to lower the volume of a filtrate that passes through a filter medium, e.g., permeable rock or a filter cake. Most attain their fluid-loss control from the presence of solvent-specific solids, or from polymers that rely on filter cake buildup and on viscoelasticity to inhibit flow into and through the formation. A variety of fluid-loss control materials have been used and evaluated, including foams, oil-soluble resins, acid-soluble particulates, graded salt slurries, linear viscoelastic polymers, and heavy metal-crosslinked polymers. Their respective comparative effects are well documented.


Another technique that has been developed to control fluid loss includes the addition of a hydrocarbon-based fluid (also referred to generically as an “oil”) to the treatment fluid in small droplets. The droplets are dispersed within the treatment fluid in an amount usually around about 1% to 5% by volume. Diesel is a common example. Other light hydrocarbons have been used as well. The droplets of the hydrocarbon-based fluid are thought to reduce the permeability of the polymer build-up in the filter cake. The oil droplets are thought to occupy space in the filter cake, but do not go into the rock to plug pore throats therein. The addition of approximately 2% to about 5% of an oil to a treatment fluid can lead to significant decreases in the amount of leak off of the treatment fluid. FIG. 1 illustrates fluid loss versus diesel oil concentration as an example. Although a reduction in fluid loss can be achieved using these methods, they also have many drawbacks. Oil droplets do not help clean up the filter cake, and may in fact, prevent or inhibit some breakers (such as oxidizers) from cleaning up the filter cake. Additionally, in a dry gas reservoir for example, the oil may become a third phase, which can damage the permeability of the formation to gas.


SUMMARY OF THE INVENTION

The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.


In one embodiment, the present invention provides a method of providing fluid loss control comprising: providing a treatment fluid; adding to the treatment fluid an acid-generating fluid loss control additive comprising an acid-generating component wherein the acid-generating fluid loss control additive forms droplets in the treatment fluid; and placing the treatment fluid into a subterranean formation.


In another embodiment, the present invention provides a method of comprising: providing a fracturing fluid that comprises an aqueous base fluid, a gelling agent, proppant particulates, and at least a plurality of droplets of acid-generating fluid loss control additives; and placing the fracturing fluid into a subterranean formation at a pressure sufficient to create or enhance a fracture therein.


In another embodiment, the present invention provides a method of degrading a filter cake comprising: providing a treatment fluid that comprises an aqueous base fluid and at least a plurality of droplets of acid-generating fluid loss control additives; placing the treatment fluid into a subterranean formation; allowing the droplets of the acid-generating fluid loss control additive to become incorporated into at least a portion of a filter cake in the subterranean formation; allowing the acid-generating fluid loss control additives to generate an acid; and allowing the acid to degrade an acid soluble degradable portion of the filter cake.


The features and advantages of the present invention will be readily apparent to those skilled in the art upon a reading of the description of the preferred embodiments, which follows.





DRAWINGS

A more complete understanding of the present disclosure and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, wherein:



FIG. 1 illustrates fluid loss versus diesel oil concentration.



FIG. 2 illustrates data discussed in the examples section.





While the present invention is susceptible to various modifications and alternative forms, specific exemplary embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit or define the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims. The figures should in no way be used to limit the meaning of the claim terms.


DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.


The acid-generating fluid loss control additives of the present invention may be added to any treatment fluid in such a way that the acid-generating fluid loss control additives form droplets within the treatment fluid. The term “droplet” as used herein refers to small dispersed, discrete, substantially immiscible drops within a treatment fluid. The size of the droplets may be important for a given application, and therefore, one should take the size of the droplets into consideration when designing the treatment. In some instances, smaller droplets, e.g., less than 500 microns, may be useful, and in some instances, those that are less than 100 microns may be even more useful. Generally speaking, coalescence into larger droplets may reduce the effectiveness of the droplets as a fluid loss control additive. For instance, it may become more difficult to incorporate them into a filter cake. The droplet size may be affected by choosing appropriate surfactants, as recognized by one skilled in the art with the benefit of this disclosure.


The acid-generating fluid loss control additives of the present invention may become incorporated within a filter cake in a subterranean formation and provide fluid loss control, and later may act as a delayed breaker for the filter cake. In addition to providing fluid loss control, one of the many advantages of the present invention is that the acid-generating fluid loss control additives of the present invention is that they can assist in degrading filter cakes that are present in the subterranean formation, e.g., those that result from fracturing fluids that build filter cakes on permeable formation surfaces. This may be especially beneficial when, for example, the filter cake has a high concentration of polymer, e.g., guar. This is advantageous because if a sufficient amount of breaker to break that polymer in the filter cake is added to a treatment fluid, the fluid will prematurely break, which is undesirable. Additionally, when the droplets become incorporated in the pore throats of the formation, the droplets may go from being substantially water-immiscible to substantially water-miscible when the degrade. Before degradation, they offer resistance to flow. After degradation, they do not impede flow because they are substantially miscible in water or the treatment fluid.


The acid-generating fluid loss control additives of the present invention may be added to any treatment fluid in which it is desirable to control fluid loss. Examples include fracturing fluids, drill-in fluids, gravel pack fluids, and fluid loss control pills. Hydraulic fracturing operations are stimulation techniques that generally involve pumping a treatment fluid (e.g., a fracturing fluid) into a well bore that penetrates a subterranean formation at a sufficient hydraulic pressure to create or enhance one or more cracks, or “fractures,” in the subterranean formation. The fracturing fluid may comprise particulates, often referred to as “proppant,” that are deposited in the fractures. The proppant particulates, inter alia, prevent the fractures from fully closing upon the release of hydraulic pressure, forming conductive channels through which fluids may flow to the well bore. Once at least one fracture is created or enhanced and the proppant particulates are substantially in place, the fracturing fluid may be “broken” (i.e., the viscosity is reduced), and the fracturing fluid may be recovered from the formation. Any fracturing fluid that is suitable for use in subterranean formations may be used in conjunction with the present invention.


The acid-generating fluid loss control additives of the present invention comprise an acid-generating component. Suitable acid generating components include esters; and ortho ethers (that may be referred to as ortho esters). Poly(ortho ethers) (that may be referred to as poly(ortho esters)); aliphatic polyesters; lactides, poly(lactides); glycolides; poly(glycolides); lactones; poly(ε-caprolactones); poly(hydroxybutyrates); anhydrides; poly(anhydrides); and poly(amino acids) may also be suitable if dissolved in an appropriate solvent that does negatively impact the subterranean formation in which they be used (e.g., they do not create an additional clean up hindrance). Derivatives and combinations of these may be suitable as well. The term “derivative” is defined herein to include any compound that is made from the base compound, for example, by replacing one atom in the base compound with another atom or group of atoms. One example of a suitable combination of acid-generating components includes a blend of an ester and an ortho ether. The acid-generating component also may comprise an esterase enzyme if desired. It is within the ability of one skilled in the art, with the benefit of this disclosure, to select a suitable acid-generating component. When used in the present invention, a preferable result is achieved if the acid-releasing degradable material degrades slowly over time as opposed to instantaneously. Preferably, these fluid loss additives are added in liquid form to the treatment fluid to form droplets within the treatment fluid.


Certain pH adjusters may be included to affect the degradation time of the acid-generating fluid loss control additives, if desired. For example, in some instances, it may be desirable to add a strong base to keep the pH relatively high at some point in the process. This may be beneficial when using an ortho ether acid-generating fluid loss control additive, for example. Any base that is suitable for use in a subterranean operation that does not adversely affect other components therein may be used. Sodium hydroxide is a suitable example. Other well-known bases may also be used.


The acid-generating fluid loss control additives of the present invention should be included in a treatment fluid in an amount sufficient to achieve the desired degree of fluid loss control. In some embodiments, this will be from about 0.1% to about 15% of the composition and in certain preferred embodiments, from about 1% to about 5% of the composition. In some embodiments, wherein emulsion properties are desired, 60% to 90% may be used.


The fluid loss control additives of the present invention may be used in conjunction with any treatment fluid in which it is desirable to control fluid loss, e.g., a fracturing fluid, etc.


The treatment fluids that may be used in conjunction with the present invention generally comprise an aqueous base fluid, a gelling agent, and sometimes a breaker. In certain embodiments, the gelling agent may comprise a “crosslinked gelling agent,” which is defined herein to mean that at least a portion of the gelling agent may be crosslinked by a crosslinking reaction comprising a crosslinking agent.


The aqueous base fluid used in the treatment fluids suitable for use with the present invention may comprise fresh water, saltwater (e.g., water containing one or more salts dissolved therein), brine, seawater, or combinations thereof. Generally, the water may be from any source, provided that it does not contain components that might adversely affect the stability and/or performance of the treatment fluids. In certain embodiments, the density of the aqueous base fluid can be increased, among other purposes, to provide additional particle transport and suspension in the treatment fluids of the present invention. In certain embodiments, the pH of the aqueous base fluid may be adjusted (e.g., by a buffer or other pH adjusting agent), among other purposes, to activate a crosslinking agent, and/or to reduce the viscosity of the treatment fluid (e.g., activate a breaker, deactivate a crosslinking agent). In these embodiments, the pH may be adjusted to a specific level, which may depend on, among other factors, the types of gelling agents, crosslinking agents, and/or breakers included in the treatment fluid. One of ordinary skill in the art, with the benefit of this disclosure, will recognize when such density and/or pH adjustments are appropriate. One should be aware of this pH and its potential effect on the fluid loss control agents of the present invention.


The gelling agents utilized in the treatment fluids may comprise any polymeric material capable of increasing the viscosity of an aqueous fluid. In certain embodiments, the gelling agent may comprise polymers that have at least two molecules that are capable of forming a crosslink in a crosslinking reaction in the presence of a crosslinking agent, and/or polymers that have at least two molecules that are so crosslinked (i.e., a crosslinked gelling agent). The gelling agents may be naturally-occurring, synthetic, or a combination thereof. In certain embodiments, suitable gelling agents may comprise polysaccharides, and derivatives thereof that contain one or more of these monosaccharide units: galactose, mannose, glucoside, glucose, xylose, arabinose, fructose, glucuronic acid, or pyranosyl sulfate. Examples of suitable polysaccharides include, but are not limited to, guar gums (e.g., hydroxyethyl guar, hydroxypropyl guar, carboxymethyl guar, carboxymethylhydroxyethyl guar, and carboxymethylhydroxypropyl guar (“CMHPG”)), cellulose derivatives (e.g., hydroxyethyl cellulose, carboxyethylcellulose, carboxymethylcellulose, and carboxymethylhydroxyethylcellulose), xanthan, diutan, scleroglucan, succinoglycan, and combinations thereof. In certain embodiments, the gelling agents comprise an organic carboxylated polymer, such as CMHPG. In certain embodiments, the derivatized cellulose is a cellulose grafted with an allyl or a vinyl monomer, such as those disclosed in U.S. Pat. Nos. 4,982,793; 5,067,565; and 5,122,549, the relevant disclosures of which are incorporated herein by reference. Additionally, polymers and copolymers that comprise one or more functional groups (e.g., hydroxyl, cis-hydroxyl, carboxylic acids, derivatives of carboxylic acids, sulfate, sulfonate, phosphate, phosphonate, amino, or amide groups) may be used.


The gelling agent may be present in the treatment fluids in an amount sufficient to provide the desired viscosity. In some embodiments, the gelling agents may be present in an amount in the range of from about 0.12% to about 2.0% by weight of the treatment fluid. In certain embodiments, the gelling agents may be present in an amount in the range of from about 0.18% to about 0.72% by weight of the treatment fluid.


In those embodiments of the present invention wherein it is desirable to crosslink the gelling agent, the treatment fluid may comprise one or more crosslinking agents. The crosslinking agents may comprise a metal ion that is capable of crosslinking at least two molecules of the gelling agent. Examples of suitable crosslinking agents include, but are not limited to, borate ions, zirconium IV ions, titanium IV ions, aluminum ions, antimony ions, chromium ions, iron ions, copper ions, and zinc ions. These ions may be provided by providing any compound that is capable of producing one or more of these ions; examples of such compounds include, but are not limited to, boric acid, disodium octaborate tetrahydrate, sodium diborate, pentaborates, ulexite, colemanite, zirconium lactate, zirconium triethanol amine, zirconium lactate triethanolamine, zirconium carbonate, zirconium acetylacetonate, zirconium malate, zirconium citrate, zirconium diisopropylamine lactate, zirconium glycolate, zirconium triethanol amine glycolate, zirconium lactate glycolate, titanium lactate, titanium malate, titanium citrate, titanium ammonium lactate, titanium triethanolamine, and titanium acetylacetonate, aluminum lactate, aluminum citrate, antimony compounds, chromium compounds, iron compounds, copper compounds, zinc compounds, and combinations thereof. In certain embodiments of the present invention, the crosslinking agent may be formulated to remain inactive until it is “activated” by, among other things, certain conditions in the fluid (e.g., pH, temperature, etc.) and/or contact with some other substance. In some embodiments, the crosslinking agent may be delayed by encapsulation with a coating (e.g., a porous coating) that delays the release of the crosslinking agent until a desired time or place. The choice of a particular crosslinking agent will be governed by several considerations that will be recognized by one skilled in the art, including but not limited to the following: the type of gelling agent included, the molecular weight of the gelling agent(s), the pH of the treatment fluid, temperature, and/or the desired time for the crosslinking agent to crosslink the gelling agent molecules.


When included, suitable crosslinking agents may be present in the treatment fluids of the present invention in an amount sufficient to provide, inter alia, the desired degree of crosslinking between molecules of the gelling agent. In certain embodiments, the crosslinking agent may be present in the treatment fluids of the present invention in an amount in the range of from about 0.0005% to about 0.2% by weight of the treatment fluid. In certain embodiments, the crosslinking agent may be present in the treatment fluids of the present invention in an amount in the range of from about 0.001% to about 0.05% by weight of the treatment fluid. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate amount of crosslinking agent to include in a treatment fluid of the present invention based on, among other things, the temperature conditions of a particular application, the type of gelling agents used, the molecular weight of the gelling agents, the desired degree of viscosification, and/or the pH of the treatment fluid.


Suitable breakers may include, but not limited to, sodium chlorite, sodium bromate, sodium persulfate, sodium peroxydisulfate, ammonium chlorite, ammonium bromate, ammonium persulfate, ammonium peroxydisulfate, potassium chlorite, potassium bromate, potassium persulfate, potassium peroxydisulfate, one or more oxidizable metal ions (i.e., a metal ion whose oxidation state can be increased by the removal of an electron, such as copper, cobalt, iron, manganese, vanadium), and the like. Examples of such additional breakers are described in U.S. Pat. No. 5,759,964 to Shuchart, et al., and U.S. Pat. No. 5,413,178 to Walker, et al., the relevant disclosures of which are herein incorporated by reference. In certain embodiments of the present invention, the breaker may be formulated to remain inactive until it is “activated” by, among other things, certain conditions in the fluid (e.g., pH, temperature, etc.) and/or contact with some other substance. In some embodiments, the breaker may be delayed by encapsulation with a coating (e.g., a porous coating through which the breaker may diffuse slowly, or a degradable coating that degrades down hole) that delays the release of the breaker until a desired time or place.


The breaker should be present in the treatment fluids in an amount sufficient to provide the desired viscosity reduction. The amount and composition of the breaker utilized in the present invention may depend upon a number of factors, including temperature, the type and/or amount of gelling agents used, the type and/or amount of crosslinking agent used, the pH of the treatment fluid, and the like. One skilled in the art, with the benefit of this disclosure, will recognize the amount and type of breaker suitable for a particular application of the present invention.


The treatment fluids optionally may comprise one or more additional additives known in the art, including, but not limited to, fluid loss control additives, gel stabilizers, gas, salts (e.g., KCl), pH-adjusting agents (e.g., buffers), corrosion inhibitors, dispersants, flocculants, acids, foaming agents, antifoaming agents, H2S scavengers, lubricants, oxygen scavengers, weighting agents, scale inhibitors, surfactants, catalysts, clay control agents, biocides, friction reducers, particulates (e.g., proppant particulates, gravel particulates), combinations thereof, and the like. For example, a gel stabilizer compromising sodium thiosulfate may be included in certain treatment fluids of the present invention. Individuals skilled in the art, with the benefit of this disclosure, will recognize the types of additives that may be suitable for a particular application of the present invention. For example, particulates may be included in the treatment fluids of the present invention in certain types of subterranean operations, including fracturing operations, gravel-packing operations, and the like.


To facilitate a better understanding of the present invention, the following examples of certain aspects of some embodiments are given. In no way should the following examples be read to limit, or define, the entire scope of the invention.


EXAMPLES

A base fluid was made according to a 30 lbs per 1000 gal of “WG-37” (a xanthan-based gelling agent available from Halliburton Energy Services, in Duncan, Okla.) ratio. The fluid was mixed in a Waring blender. The pH of the fluid was adjusted to 12 by the addition of a base for the crosslinker to be added later. 40 lbs per 1000 gal of 25 micron (median diameter) polylactic acid particles were added for building a filter cake. The following were then added: 2% by volume “WS-44,” which is a surfactant that can be used to disperse the substantially immiscible fluid loss material in the fluid, and 5% by volume “AccuBreak PR,” which is a substantially immiscible delayed acid generator that can improve fluid loss control. Both products are available from Halliburton Energy Services in Duncan Okla. Then, 0.5% by volume “CL-23” crosslinker (available from Halliburton Energy Services in Duncan Okla.) was added. The resultant fluid was allowed to crosslink. A fluid loss test was then performed in a Fann HPHT Cell with 500 psi differential pressure at 180° F. using a 5 micron Aloxit disk. Fluid loss was measured over time. FIG. 2 depicts the results. The bottom curve in FIG. 2 is shows the fluid loss data from the fluid described in this example above, with the fluid loss control material added. The top curve is the fluid loss data from a second fluid that was made in the same manner that did not include the “WS-44” and “AccuBreak PR” products described above.


Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values, and set forth every range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Thus, the present invention is well adapted to carry out the objects and attain the ends and advantages mentioned as well as those that are inherent therein. While numerous changes may be made by those skilled in the art, such changes are encompassed within the spirit and scope of this invention as defined by the appended claims.

Claims
  • 1. A method of providing fluid loss control comprising: providing a treatment fluid;adding to the treatment fluid an acid-generating fluid loss control additive comprising an acid-generating component wherein the acid-generating fluid loss control additive forms small dispersed, discrete, substantially immiscible liquid drops in the treatment fluid; andthereafter, placing the treatment fluid into a subterranean formation.
  • 2. The method of claim 1 wherein the drops are less than 500 microns.
  • 3. The method of claim 1 wherein the at least one drop becomes incorporated in a porethroat of the subterranean formation.
  • 4. The method of claim 1 wherein the treatment fluid is a fracturing fluid, a drill-in fluid, a gravel pack fluid, or a fluid loss control pill.
  • 5. The method of claim 1 wherein the acid-generating component comprises at least one component selected from the group consisting of: an ester; an ortho ether; a poly(ortho ether); an aliphatic polyester; a lactide; a poly(lactide); a glycolide; a poly(glycolide); a lactone; a poly(s-caprolactone); a poly(hydroxybutyrate); an anhydride; a poly(anhydride); a poly(amino acid); and any derivative thereof.
  • 6. The method of claim 1 wherein the treatment fluid comprises at least one additive selected from the group consisting of: a fluid loss control additive; a gel stabilizer; a gas; a salt; a pH-adjusting agent; a breaker; a corrosion inhibitor; a dispersant; a flocculant; an acid; a foaming agent; an antifoaming agent; an H2S scavenger; a lubricant; an oxygen scavenger; a weighting agent; a scale inhibitor; a surfactant; a catalyst; a clay control agent; a biocide; a friction reducer; a particulate; a proppant particulate; and a gravel particulate.
  • 7. The method of claim 1 wherein the treatment fluid comprises an aqueous base fluid.
  • 8. The method of claim 1 wherein the treatment fluid comprises a gelling agent or a crosslinked gelling agent.
  • 9. The method of claim 1, wherein the acid-generating fluid loss control additive is added in liquid form to the treatment fluid.
  • 10. A method comprising: providing a fracturing fluid that comprises an aqueous base fluid, a gelling agent, proppant particulates, and at least a plurality of small dispersed, discrete, substantially immiscible liquid drops of acid-generating fluid loss control additives; andthereafter, placing the fracturing fluid into a subterranean formation at a pressure sufficient to create or enhance a fracture therein.
  • 11. The method of claim 10 wherein the drops are less than 500 microns.
  • 12. The method of claim 10 wherein the at least one drop becomes incorporated in a porethroat of the subterranean formation.
  • 13. The method of claim 10 wherein the acid-generating component comprises at least one component selected from the group consisting of: an ester; an ortho ether; a poly(ortho ether); an aliphatic polyester; a lactide; a poly(lactide); a glycolide; a poly(glycolide); a lactone; a poly(-caprolactone); a poly(hydroxybutyrate); an anhydride; a poly(anhydride); a poly(amino acid); and any derivative thereof.
  • 14. The method of claim 10 wherein the fracturing fluid comprises at least one additive selected from the group consisting of: a fluid loss control additive; a gel stabilizer; a gas; a salt; a pH-adjusting agent; a breaker; a corrosion inhibitor; a dispersant; a flocculant; an acid; a foaming agent; an antifoaming agent; an H2S scavenger; a lubricant; an oxygen scavenger; a weighting agent; a scale inhibitor; a surfactant; a catalyst; a clay control agent; a biocide; a friction reducer; a particulate; and a gravel particulate.
US Referenced Citations (363)
Number Name Date Kind
2238671 Woodhouse Apr 1941 A
2703316 Palmer Mar 1955 A
3173484 Huitt et al. Mar 1965 A
3195635 Fast Jul 1965 A
3272650 MacVittie Sep 1966 A
3302719 Fischer Feb 1967 A
3364995 Atkins et al. Jan 1968 A
3366178 Malone et al. Jan 1968 A
3455390 Gallus Jul 1969 A
3784585 Schmitt et al. Jan 1974 A
3819525 Hattenbrun Jun 1974 A
3828854 Templeton et al. Aug 1974 A
3836465 Rhudy et al. Sep 1974 A
3868998 Lybarger et al. Mar 1975 A
3912692 Casey et al. Oct 1975 A
3948672 Harnsberger Apr 1976 A
3955993 Curtice May 1976 A
3960736 Free et al. Jun 1976 A
3968840 Tate Jul 1976 A
3986355 Klaeger Oct 1976 A
3998272 Maly Dec 1976 A
3998744 Arnold et al. Dec 1976 A
4010071 Colegrove Mar 1977 A
4068718 Cooke, Jr. et al. Jan 1978 A
4169798 DeMartino Oct 1979 A
4172066 Zweigle et al. Oct 1979 A
4261421 Watanabe Apr 1981 A
4265673 Pace et al. May 1981 A
4299825 Lee Nov 1981 A
4387769 Erbstoesser et al. Jun 1983 A
4460052 Gockel Jul 1984 A
4470915 Conway Sep 1984 A
4498995 Gockel Feb 1985 A
4502540 Byham Mar 1985 A
4506734 Nolte Mar 1985 A
4521316 Sikorski Jun 1985 A
4526695 Erbstoesser et al. Jul 1985 A
4632876 Laird et al. Dec 1986 A
4694905 Armbruster Sep 1987 A
4715967 Bellis Dec 1987 A
4716964 Erbstoesser et al. Jan 1988 A
4767706 Levesque Aug 1988 A
4772346 Anderson et al. Sep 1988 A
4785884 Armbruster Nov 1988 A
4793416 Mitchell Dec 1988 A
4797262 Dewitz Jan 1989 A
4809783 Hollenbeck et al. Mar 1989 A
4817721 Pober Apr 1989 A
4822500 Dobson, Jr. et al. Apr 1989 A
4829100 Murphey et al. May 1989 A
4836940 Alexander Jun 1989 A
4843118 Lai et al. Jun 1989 A
4848467 Cantu et al. Jul 1989 A
4863980 Cowan et al. Sep 1989 A
4886354 Welch et al. Dec 1989 A
4894231 Moreau et al. Jan 1990 A
4957165 Cantu et al. Sep 1990 A
4961466 Himes et al. Oct 1990 A
4982793 Holtmyer et al. Jan 1991 A
4986353 Clark et al. Jan 1991 A
4986354 Cantu et al. Jan 1991 A
4986355 Casad et al. Jan 1991 A
5034139 Reid et al. Jul 1991 A
5067565 Holtmyer et al. Nov 1991 A
5082056 Tackett, Jr. Jan 1992 A
5122549 Holtmyer et al. Jun 1992 A
5142023 Gruber et al. Aug 1992 A
5152781 Tang et al. Oct 1992 A
5161615 Hutchins et al. Nov 1992 A
5203834 Hutchins et al. Apr 1993 A
5213446 Dovan May 1993 A
5216050 Sinclair Jun 1993 A
5247059 Gruber et al. Sep 1993 A
5249628 Surjaatmadja Oct 1993 A
5251697 Shuler Oct 1993 A
5295542 Cole et al. Mar 1994 A
5304620 Holtmyer et al. Apr 1994 A
5314031 Hale et al. May 1994 A
5325923 Surjaatmadja et al. Jul 1994 A
5330005 Card et al. Jul 1994 A
5359026 Gruber Oct 1994 A
5360068 Sprunt et al. Nov 1994 A
5363916 Himes et al. Nov 1994 A
5373901 Norman et al. Dec 1994 A
5386874 Laramay et al. Feb 1995 A
5396957 Surjaatmadja et al. Mar 1995 A
5402846 Jennings, Jr. et al. Apr 1995 A
5413178 Walker et al. May 1995 A
5439055 Card et al. Aug 1995 A
5460226 Lawton et al. Oct 1995 A
5464060 Hale et al. Nov 1995 A
5475080 Gruber et al. Dec 1995 A
5484881 Gruber et al. Jan 1996 A
5487897 Polson et al. Jan 1996 A
5492177 Yeh et al. Feb 1996 A
5496557 Feijen et al. Mar 1996 A
5497830 Boles et al. Mar 1996 A
5499678 Surjaatmadja et al. Mar 1996 A
5501276 Weaver et al. Mar 1996 A
5505787 Yamaguchi Apr 1996 A
5512071 Yam et al. Apr 1996 A
5536807 Gruber et al. Jul 1996 A
5555936 Pirri et al. Sep 1996 A
5591700 Harris et al. Jan 1997 A
5594095 Gruber et al. Jan 1997 A
5602083 Gabrysch et al. Feb 1997 A
5604186 Hunt et al. Feb 1997 A
5607905 Dobson, Jr. et al. Mar 1997 A
5613558 Dillenbeck Mar 1997 A
5670473 Scepanski Sep 1997 A
5697440 Weaver et al. Dec 1997 A
5698322 Tsai et al. Dec 1997 A
5723416 Liao Mar 1998 A
5759964 Shuchart et al. Jun 1998 A
5765642 Surjaatmadja Jun 1998 A
5783527 Dobson, Jr. et al. Jul 1998 A
5791415 Nguyen et al. Aug 1998 A
5799734 Normal et al. Sep 1998 A
5833000 Weaver et al. Nov 1998 A
5849401 El-Afandi et al. Dec 1998 A
5853048 Weaver et al. Dec 1998 A
5893416 Read Apr 1999 A
5908073 Nguyen et al. Jun 1999 A
5916849 House Jun 1999 A
5924488 Nguyen et al. Jul 1999 A
5964291 Bourne et al. Oct 1999 A
5977030 House Nov 1999 A
5979557 Card et al. Nov 1999 A
5996693 Heathman Dec 1999 A
6004400 Bishop et al. Dec 1999 A
6024170 McCabe et al. Feb 2000 A
6028113 Scepanski Feb 2000 A
6047772 Weaver et al. Apr 2000 A
6110875 Tjon-Joe-Pin et al. Aug 2000 A
6114410 Betzold Sep 2000 A
6123159 Brookey et al. Sep 2000 A
6123965 Jacob et al. Sep 2000 A
6131661 Conner et al. Oct 2000 A
6135987 Tsai et al. Oct 2000 A
6143698 Murphey et al. Nov 2000 A
6148917 Brookey et al. Nov 2000 A
6162766 Muir et al. Dec 2000 A
6169058 Le et al. Jan 2001 B1
6172011 Card et al. Jan 2001 B1
6189615 Sydansk Feb 2001 B1
6202751 Chatterji et al. Mar 2001 B1
6209643 Nguyen et al. Apr 2001 B1
6209646 Reddy et al. Apr 2001 B1
6214773 Harris et al. Apr 2001 B1
6242390 Mitchell et al. Jun 2001 B1
6260622 Blok et al. Jul 2001 B1
6291013 Gibson et al. Sep 2001 B1
6300286 Dobson, Jr. et al. Oct 2001 B1
6302209 Thompson et al. Oct 2001 B1
6308788 Patel et al. Oct 2001 B1
6311773 Todd et al. Nov 2001 B1
6323307 Bigg et al. Nov 2001 B1
6326458 Gruber et al. Dec 2001 B1
6328105 Betzold Dec 2001 B1
6330917 Chatterji et al. Dec 2001 B2
6357527 Norman et al. Mar 2002 B1
6364945 Chatterji et al. Apr 2002 B1
6380138 Ischy et al. Apr 2002 B1
6387986 Moradi-Araghi et al. May 2002 B1
6390195 Nguyen et al. May 2002 B1
6394185 Constien May 2002 B1
6422314 Todd et al. Jul 2002 B1
6422326 Brookey et al. Jul 2002 B1
6432155 Swazey et al. Aug 2002 B1
6454003 Chang et al. Sep 2002 B1
6485947 Rajgarhia et al. Nov 2002 B1
6488763 Brothers et al. Dec 2002 B2
6494263 Todd Dec 2002 B2
6508305 Brannon et al. Jan 2003 B1
6509301 Vollmer et al. Jan 2003 B1
6527051 Reddy et al. Mar 2003 B1
6554071 Reddy et al. Apr 2003 B1
6566310 Chan May 2003 B2
6569814 Brady et al. May 2003 B1
6578630 Simpson et al. Jun 2003 B2
6599863 Palmer et al. Jul 2003 B1
6667279 Hessert et al. Dec 2003 B1
6669771 Tokiwa et al. Dec 2003 B2
6681856 Chatterji et al. Jan 2004 B1
6686328 Binder Feb 2004 B1
6691780 Nguyen et al. Feb 2004 B2
6702023 Harris et al. Mar 2004 B1
6710019 Sawdon et al. Mar 2004 B1
6716797 Brookey Apr 2004 B2
6737385 Todd et al. May 2004 B2
6761218 Nguyen et al. Jul 2004 B2
6763888 Harris et al. Jul 2004 B1
6764981 Eoff et al. Jul 2004 B1
6793018 Dawson et al. Sep 2004 B2
6793730 Reddy et al. Sep 2004 B2
6806235 Mueller et al. Oct 2004 B1
6817414 Lee Nov 2004 B2
6818594 Freeman et al. Nov 2004 B1
6837309 Boney et al. Jan 2005 B2
6883608 Parlar et al. Apr 2005 B2
6896058 Munoz, Jr. et al. May 2005 B2
6904971 Brothers et al. Jun 2005 B2
6949491 Cooke, Jr. Sep 2005 B2
6959767 Horton et al. Nov 2005 B2
6978838 Parlar et al. Dec 2005 B2
6981552 Reddy et al. Jan 2006 B2
6983801 Dawson et al. Jan 2006 B2
6987083 Phillippi et al. Jan 2006 B2
6997259 Nguyen Feb 2006 B2
7007752 Reddy et al. Mar 2006 B2
7021337 Markham Apr 2006 B2
7032663 Nguyen Apr 2006 B2
7036586 Roddy et al. May 2006 B2
7036587 Munoz, Jr. et al. May 2006 B2
7044220 Nguyen et al. May 2006 B2
7044224 Nguyen May 2006 B2
7063151 Nguyen et al. Jun 2006 B2
7066258 Justus et al. Jun 2006 B2
7069994 Cooke, Jr. Jul 2006 B2
7080688 Todd et al. Jul 2006 B2
7093664 Todd et al. Aug 2006 B2
7096947 Todd et al. Aug 2006 B2
7101829 Guichard et al. Sep 2006 B2
7131491 Blauch et al. Nov 2006 B2
7140438 Frost et al. Nov 2006 B2
7147067 Getzlaf et al. Dec 2006 B2
7151077 Prud'homme et al. Dec 2006 B2
7156174 Roddy et al. Jan 2007 B2
7165617 Lord et al. Jan 2007 B2
7168489 Frost et al. Jan 2007 B2
7172022 Reddy et al. Feb 2007 B2
7178596 Blauch et al. Feb 2007 B2
7195068 Todd Mar 2007 B2
7204312 Roddy et al. Apr 2007 B2
7219731 Sullivan et al. May 2007 B2
7228904 Todd et al. Jun 2007 B2
7256159 Guichard et al. Aug 2007 B2
7261156 Nguyen et al. Aug 2007 B2
7264051 Nguyen et al. Sep 2007 B2
7267170 Mang et al. Sep 2007 B2
7299876 Lord et al. Nov 2007 B2
7303014 Reddy et al. Dec 2007 B2
7306037 Nguyen et al. Dec 2007 B2
7322412 Badalamenti et al. Jan 2008 B2
7337839 Ayoub et al. Mar 2008 B2
7353876 Savery et al. Apr 2008 B2
7353879 Todd et al. Apr 2008 B2
7380600 Willberg et al. Jun 2008 B2
7413017 Nguyen et al. Aug 2008 B2
7448450 Luke et al. Nov 2008 B2
7455112 Moorehead et al. Nov 2008 B2
7461697 Todd et al. Dec 2008 B2
7475728 Pauls et al. Jan 2009 B2
7484564 Welton et al. Feb 2009 B2
7497258 Savery et al. Mar 2009 B2
7497278 Schriener et al. Mar 2009 B2
7506689 Surjaatmadja et al. Mar 2009 B2
7547665 Welton et al. Jun 2009 B2
7595280 Welton et al. Sep 2009 B2
7598208 Todd Oct 2009 B2
7608566 Saini et al. Oct 2009 B2
7608567 Saini Oct 2009 B2
20010016562 Muir et al. Aug 2001 A1
20020036088 Todd Mar 2002 A1
20020119169 Angel et al. Aug 2002 A1
20020125012 Dawson et al. Sep 2002 A1
20030054962 England et al. Mar 2003 A1
20030060374 Cooke, Jr. Mar 2003 A1
20030114314 Ballard et al. Jun 2003 A1
20030130133 Vollmer Jul 2003 A1
20030147965 Bassett et al. Aug 2003 A1
20030188766 Banerjee et al. Oct 2003 A1
20030230407 Vijn et al. Dec 2003 A1
20030234103 Lee et al. Dec 2003 A1
20040014606 Parlar et al. Jan 2004 A1
20040014607 Sinclair et al. Jan 2004 A1
20040040706 Hossaini et al. Mar 2004 A1
20040055747 Lee Mar 2004 A1
20040070093 Mathiowitz et al. Apr 2004 A1
20040094300 Sullivan et al. May 2004 A1
20040099416 Vijn et al. May 2004 A1
20040106525 Willberg et al. Jun 2004 A1
20040138068 Rimmer et al. Jul 2004 A1
20040152601 Still et al. Aug 2004 A1
20040152602 Boles Aug 2004 A1
20040162386 Altes et al. Aug 2004 A1
20040170836 Bond et al. Sep 2004 A1
20040214724 Todd et al. Oct 2004 A1
20040216876 Lee Nov 2004 A1
20040231845 Cooke, Jr. Nov 2004 A1
20040261993 Nguyen Dec 2004 A1
20040261995 Nguyen et al. Dec 2004 A1
20040261996 Munoz, Jr. et al. Dec 2004 A1
20040261999 Nguyen Dec 2004 A1
20050006095 Justus et al. Jan 2005 A1
20050028976 Nguyen Feb 2005 A1
20050034861 Saini et al. Feb 2005 A1
20050034865 Todd et al. Feb 2005 A1
20050034868 Frost et al. Feb 2005 A1
20050045328 Frost et al. Mar 2005 A1
20050051330 Nguyen Mar 2005 A1
20050056423 Todd et al. Mar 2005 A1
20050059556 Munoz, Jr. et al. Mar 2005 A1
20050059557 Todd et al. Mar 2005 A1
20050059558 Blauch et al. Mar 2005 A1
20050103496 Todd et al. May 2005 A1
20050126780 Todd et al. Jun 2005 A1
20050126785 Todd Jun 2005 A1
20050130848 Todd et al. Jun 2005 A1
20050161220 Todd et al. Jul 2005 A1
20050167104 Roddy et al. Aug 2005 A1
20050167105 Roddy et al. Aug 2005 A1
20050167107 Roddy et al. Aug 2005 A1
20050183741 Surjaatmadja et al. Aug 2005 A1
20050205258 Reddy et al. Sep 2005 A1
20050205265 Todd et al. Sep 2005 A1
20050205266 Todd et al. Sep 2005 A1
20050252659 Sullivan et al. Nov 2005 A1
20050272613 Cooke, Jr. Dec 2005 A1
20050277554 Blauch et al. Dec 2005 A1
20060016596 Pauls et al. Jan 2006 A1
20060032633 Nguyen Feb 2006 A1
20060046938 Harris et al. Mar 2006 A1
20060048938 Kalman Mar 2006 A1
20060065397 Nguyen et al. Mar 2006 A1
20060105917 Munoz, Jr. May 2006 A1
20060105918 Munoz, Jr. et al. May 2006 A1
20060108150 Luke et al. May 2006 A1
20060169182 Todd et al. Aug 2006 A1
20060169448 Savery et al. Aug 2006 A1
20060169450 Mang et al. Aug 2006 A1
20060169452 Savery et al. Aug 2006 A1
20060169453 Savery et al. Aug 2006 A1
20060172893 Todd et al. Aug 2006 A1
20060172894 Mang et al. Aug 2006 A1
20060172895 Mang et al. Aug 2006 A1
20060185847 Saini et al. Aug 2006 A1
20060185848 Surjaatmadja et al. Aug 2006 A1
20060205608 Todd Sep 2006 A1
20060234873 Ballard Oct 2006 A1
20060243449 Welton et al. Nov 2006 A1
20060247135 Welton et al. Nov 2006 A1
20060254774 Saini et al. Nov 2006 A1
20060258543 Saini Nov 2006 A1
20060258544 Saini Nov 2006 A1
20060276345 Todd et al. Dec 2006 A1
20060283597 Schriener et al. Dec 2006 A1
20070042912 Welton et al. Feb 2007 A1
20070049501 Saini et al. Mar 2007 A1
20070066492 Funkhouser et al. Mar 2007 A1
20070066493 Funkhouser et al. Mar 2007 A1
20070078063 Munoz, Jr. Apr 2007 A1
20070078064 Munoz et al. Apr 2007 A1
20070238623 Saini et al. Oct 2007 A1
20070281868 Pauls et al. Dec 2007 A1
20080026955 Munoz et al. Jan 2008 A1
20080026959 Munoz et al. Jan 2008 A1
20080026960 Munoz et al. Jan 2008 A1
20080027157 Munoz et al. Jan 2008 A1
20080070810 Mang Mar 2008 A1
20080169102 Carbajal et al. Jul 2008 A1
20090062157 Munoz et al. Mar 2009 A1
20090258798 Munoz Oct 2009 A1
Foreign Referenced Citations (24)
Number Date Country
0 510 762 Oct 1992 EP
0 879 935 Nov 1998 EP
0 879 935 Feb 1999 EP
1 413 710 Apr 2004 EP
2 412 389 Mar 2004 GB
2004181820 Jul 2004 JP
WO 9315127 Aug 1993 WO
WO 9407949 Apr 1994 WO
WO 9408078 Apr 1994 WO
WO 9408090 Apr 1994 WO
WO 9509879 Apr 1995 WO
WO 9711845 Apr 1997 WO
WO 9927229 Jun 1999 WO
WO 0057022 Sep 2000 WO
WO 0102698 Jan 2001 WO
WO 0187797 Nov 2001 WO
WO 0194744 Dec 2001 WO
WO 0255843 Jan 2002 WO
WO 0212674 Feb 2002 WO
WO 03027431 Apr 2003 WO
WO 03027431 Apr 2003 WO
WO 2004007905 Jan 2004 WO
WO 2004037946 May 2004 WO
WO 2004038176 May 2004 WO
Related Publications (1)
Number Date Country
20080139415 A1 Jun 2008 US